For the first timehttps://innovationtoronto.com/wp-content/uploads/2019/10/213780_webwe4.jpg, scientists have identified a simple way that can effectively transport medication into the brain – which could lead to improved treatments for neurological and neurodegenerative diseases.
In a study published today in Nature Communications, scientists from Newcastle University, UK, have led an international team in a major breakthrough in unlocking the secrets of how medications can infiltrate the brain.
Blood capillaries in the brain are not permeable to many drugs and the majority are excluded from the brain by a protective barrier, called the blood-brain-barrier (BBB), and current treatment options are risky.
Some viruses, however, have found ways to bypass the BBB and enter the brain. To treat certain neurological and neurodegenerative diseases, medication has to use modified viruses to bypass this barrier and deliver drugs to the area.
The team has now engineered small particles, similar to the size of viruses, from a peptide that can behave like a carrier to the brain and can be packed with drugs for intravenous injection.
Professor Moein Moghimi, who led the research, said: “Crossing the blood-brain-barrier has hindered the industry from effectively addressing central nervous system diseases, including brain tumours, and many neurological diseases like Parkinson’s, Alzheimer’s and Huntington’s.
“This breakthrough – based on more than 10 years of research – has significant implications for crossing BBB and other biological barriers that have created challenges for drug delivery.
“Our breakthrough allows for minimally invasive combination delivery through an intravenous injection of various drugs, peptides and nucleic acid therapeutics to the brain.”
At present, treatment of neurological disorders involves difficulties in ‘packaging’ viruses safely and medication is usually administered by injection into the cerebrospinal fluid, which is not without risks.
The new technological breakthrough in delivering genetic materials to cells in the brain has used a peptide component from a virus that targets the brain (a bacteriophage fd). The peptide was synthesised and modified slightly, and when water was added it spontaneously formed a ‘small, hairy particle’.
Scientists found that when the developed particle was injected into a mouse model, the system targeted the brain, crossing the blood-brain-barrier, reaching neurons and microglia cells in the brain.
Professor Moghimi added: “We are very excited by our research – our delivery system is versatile and amenable to modifications, so, in principle, we can hopefully address shortfalls in drug delivery to the brain through intravenous injection.
“We have a long way to go, but we hope that our technology platform may open up many opportunities to address neurodegenerative diseases with modern therapeutics and genetic drugs.”
Through the mouse model, scientists found their technique was safe. Further research will test the technology in animal disease models in preparation for clinical trials.
Gary Leo, SMDG’s SVP of Corporate Development and former national president and CEO of the ALS Association, USA, said: “Bearing in mind the fact that neurological disorders are growing in incidence faster than any other disease class worldwide, governments will face a huge burden and increasing demands for treatment and support services.
“New knowledge is required to develop effective treatment strategies, and the new technology reported in Nature Communications is a promising achievement to fulfil these goals.”
The Latest on: Blood-brain-barrier
via Google News
The Latest on: Blood-brain-barrier
- Restoring Blood-Brain Barrier P-Glycoprotein Reduces Brain Amyloid-β in a Mouse Model of Alzheimer's Diseaseon October 12, 2021 at 1:11 pm
Reduced clearance of amyloid-β (Aβ) from brain partly underlies increased Aβ brain accumulation in Alzheimer's disease (AD). The mechanistic basis for this pathology is unknown, but recent ...
- Blood Brain Barrier Technologies Market 2021 Healthcare to Occupy a Significant Market Share by 2028 – The Insights Partnerson October 12, 2021 at 10:23 am
The Insight Partners announces the research on Global Blood Brain Barrier Technologies Market as it covers the key boundaries required for your Research Need This Global Blood Brain Barrier ...
- Inflammatory Cell Migration into the Central Nervous System: A Few New Twists on an Old Taleon October 12, 2021 at 8:23 am
Understanding the mechanisms of leukocyte trafficking into the brain might provide insights into how to modulate pathologic immune responses or enhance host protective mechanisms in neuroinflammatory ...
- First-in-Class Nerve Agent Antidote Crosses Blood-Brain Barrier to Aid Central Nervous Systemon October 12, 2021 at 7:58 am
Chemical weapon nerve agents like Sarin or Novichok typically function by blocking the transmission of messages from the central nervous system to the ...
- Study finds clean air matters for healthy brainon October 9, 2021 at 4:00 pm
Research on air pollution and cognitive decline has indicated that cleaner air may reduce the risk for Alzheimer's and other dementias.The findings of the study were published in ‘The Journal of the ...
- The Traumatic Brain Injury Therapeutics Market To Leverage The Digital Disruption Waveon October 8, 2021 at 7:51 am
Traumatic Brain Injury or TBI is sustained from severe or mild damage to the brain tissue from accidents or assaults. In North America, over 1.7 mil ...
- TTUHSC researcher investigates ways to enhance neurolysin activity in the brainon October 8, 2021 at 5:12 am
TTUHSC’s Vardan Karamyan, Ph.D., has spent years researching and collaborating with others to develop an effective treatment for stroke that focuses on the use of a peptidase known as neurolysin. In ...
- Drugs That Improve Outcomes of Brain Tumorson October 7, 2021 at 11:20 am
Outcomes of central nervous system tumors may be improved with DNA alkylation drugs for adolescents and young adults.
- Cancer drug restores blood-brain barrier to reverse Alzheimer's in miceon October 5, 2021 at 8:11 pm
As researchers continue to search for the causes behind Alzheimer's disease and age-related dementia, one possibility is that a leaky blood-brain barrier could have a role to play, allowing for the ...
- Exosome delivery of an anti-HIV drug to the brainon September 30, 2021 at 10:00 am
The body has a remarkable ability to prevent foreign objects, such as toxins or other pathogens, from entering the brain. This is accomplished through seve | Drug Discovery And Development ...
via Bing News